Alix M.B. Lacoste
Alix M.B. Lacoste
Sonstige NamenAlix M. Lacoste
Invitae, Harvard University, IBM Watson Health, BenevolentAI
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Whole-brain activity mapping onto a zebrafish brain atlas
O Randlett, CL Wee, EA Naumann, O Nnaemeka, D Schoppik, ...
Nature methods 12 (11), 1039-1046, 2015
Applications of machine learning to diagnosis and treatment of neurodegenerative diseases
MA Myszczynska, PN Ojamies, AMB Lacoste, D Neil, A Saffari, R Mead, ...
Nature reviews neurology 16 (8), 440-456, 2020
Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis
N Bakkar, T Kovalik, I Lorenzini, S Spangler, A Lacoste, K Sponaugle, ...
Acta neuropathologica 135, 227-247, 2018
A convergent and essential interneuron pathway for Mauthner-cell-mediated escapes
AMB Lacoste, D Schoppik, DN Robson, M Haesemeyer, R Portugues, ...
Current Biology 25 (11), 1526-1534, 2015
Zebrafish oxytocin neurons drive nocifensive behavior via brainstem premotor targets
CL Wee, M Nikitchenko, WC Wang, SJ Luks-Morgan, E Song, JA Gagnon, ...
Nature neuroscience 22 (9), 1477-1492, 2019
Interpretable graph convolutional neural networks for inference on noisy knowledge graphs
D Neil, J Briody, A Lacoste, A Sim, P Creed, A Saffari
arXiv preprint arXiv:1812.00279, 2018
Preclinical validation of therapeutic targets predicted by tensor factorization on heterogeneous graphs
S Paliwal, A de Giorgio, D Neil, JB Michel, AMB Lacoste
Scientific reports 10 (1), 18250, 2020
Expert-augmented computational drug repurposing identified baricitinib as a treatment for COVID-19
DP Smith, O Oechsle, MJ Rawling, E Savory, AMB Lacoste, ...
Frontiers in pharmacology 12, 709856, 2021
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease
TH Johnston, AMB Lacoste, NP Visanji, AE Lang, SH Fox, JM Brotchie
Neuropharmacology 147, 11-27, 2019
Identifying drugs with disease‐modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology
LC Maclagan, NP Visanji, Y Cheng, M Tadrous, AMB Lacoste, LV Kalia, ...
Pharmacoepidemiology and drug safety 29 (8), 864-872, 2020
Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans
KS Chen, K Menezes, JB Rodgers, DM O’Hara, N Tran, K Fujisawa, ...
Molecular Neurodegeneration 16, 1-25, 2021
Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson
S Hatz, S Spangler, A Bender, M Studham, P Haselmayer, AMB Lacoste, ...
PloS one 14 (4), e0214619, 2019
Graph neutral networks with attention
P Creed, SIM Aaron, A Alamdari, J Briody, D Neil, A Lacoste
US Patent App. 17/041,625, 2021
Using artificial intelligence to identify anti‐hypertensives as possible disease modifying agents in Parkinson's disease
NP Visanji, P Madan, AMB Lacoste, I Buleje, Y Han, S Spangler, LV Kalia, ...
Pharmacoepidemiology and Drug Safety 30 (2), 201-209, 2021
Rate of pathogenic germline variants in patients with lung cancer
S Sorscher, J LoPiccolo, B Heald, E Chen, SL Bristow, ST Michalski, ...
JCO Precision Oncology 7, e2300190, 2023
Machine learning for ranking candidate subjects based on a training set
AM Lacoste, WS Spangler
US Patent 11,182,692, 2021
Classification of cardiovascular proteins involved in coronary atherosclerosis and heart failure using Watson’s cognitive computing technology
CT Ruff, A Lacoste, F Nordio, CL Fanola, MG Silverman, E Argentinis, ...
Circulation 136 (suppl_1), A16678-A16678, 2017
Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia
TH Johnston, AMB Lacoste, P Ravenscroft, J Su, S Tamadon, M Seifi, ...
Neuropharmacology 248, 109880, 2024
Computation of longitudinal phenotypes in 466 individuals with a developmental and epileptic encephalopathy enables clinical trial readiness
E Brimble, J Kim, RL Martin, D McKnight, AMB Lacoste
medRxiv, 2023.03. 02.23286645, 2023
Ranking biological entity pairs by evidence level
DL Neil, AMB LaCoste, A DeGiorgio, I Churcher, RD Sutherland, Y Gao
US Patent App. 17/625,113, 2022
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20